In a time of unprecedented public fear and distrust of institutions, life science companies must be more careful than ever in cultivating KOL relationships that can lend credibility to their products in the minds of the medical community. As regulations grow more strict, and demand for niche products and personalized treatment rises, KOLs are set to play an even more important role in each stage of the drug life cycle.
DGE’s KOL & Thought Leader Engagement Summit is the only conference for life science professionals that focuses specifically on building and getting the most out of these partnerships. Don’t miss out on this unique learning and networking opportunity, presented on a proven interactive streaming platform!
- Gain knowledge from top experts on how to effectively engage with KOLs
- Identify best strategies to establish and maintain meaningful relationships with KOLs
- Learn about legal regulations and how to stay in compliance when engaging with KOLs
- Learn about different approaches and methodologies
- Examine the different platforms used to identify, track, and map KOLs
This livestream conference is designed for life science professionals with the following responsibilities:
- KOL Management & Engagement
- Medical Science Liaisons (MSLs)
- Medical Affairs
- Opinion/Thought Leader Relations
- Advisory Boards/Speaker Programs
- Scientific Communication/Affairs
- Speaker Programs
- Commercialization Strategy
- Brand/Portfolio Management
- Speaker Bureau Training/Management
- Field Medical
- Medical Education
- External Engagement
- Advisory Board Service Providers
- KOL Software Mapping Services
- KOL Technology Providers
- Promotional Regulatory Affairs
- Medical Publications
- Global Relations
Everything we do is intended to impact a treatment eco-system by addressing market needs in some ways. KOLs play many important roles but an essential first step is to fully understand the system, the disease community, in which they operate. This is fundamentally a data challenge. This session will provide practical examples of data-driven engagement including:
- How data perspectives illuminate actionable insights and opportunities
- How local ecosystems and KOLs can impact clinical trial accrual and treatment practices
- How data can find missing patients and identify educational needs
- How to engage KOLs in the context of all of the above
- Re-think KOL touchpoints as a KOL-centric journey
- Leverage scientific exchange efficiently and effectively along the journey
- Demonstrate impact with unique insights/stories
- Review practical yet innovative approaches to apply in real life
MSLs engage with external stakeholders and are key in developing and building relationships with KOLs. How can you make sure you have the right team members and training at the stage where you need them?
- Invest in developing competencies of the MSL team
- Equip MSLs with superior communication skills and a comprehensive understanding of the market situation
- Train them to be fluent in all relevant digital tools and platforms
An exploration of how Medical affairs organizations continue to further their use of data and analytics in demonstrating value. The availability of novel data sources holds the promise of enhancing strategies and engagement impact. When considering these new sources of knowledge, one must ask, what is the strategic application of healthcare claims via medical affairs?
1. Medical Claims and Medical Affairs: Leaders across the (bio)pharmaceutical industry are beginning to see the potential medical claims offer to those driving awareness and understanding of novel approaches to patient care. However, the questions must be asked, how can this data be used effectively and how will it enhance insights into the world’s experts, improving one’s ability to identify, prioritize, and engage differently?
2. Understanding Care Relationships: Understanding how patients are referred is just another foundational piece of information that medical affairs should understand and apply strategically. This evolving dynamic could provide opportunities for a company to improve education, resource deployment, and therapeutic interventions.
3. Comparing Scientific Expertise: Unlike academic research, clinical practice isn’t about developing new innovations or furthering existing knowledge. It’s about the current standard of care and understanding how evidence has impacted decision-making. Identifying clinical leaders provides a new avenue to share emerging evidence to enhance care choices in the future.